A research center in California, Kythera Biopharmaceuticals, has been developing their new product ATX-101 (fat reduction drug) for years now. It is currently in phase three (the phase before the market) but is still suspected to be in trial phase for a some years.
They are actually suggesting that Deoxycholite alone is helping the lipomas to shrink and that Phosphatidylcholine is actually inhibiting the cell death. Source: http://www.kytherabiopharma.com/pdf/200 ... n_vivo.pdf
One hundred twenty-nine subjects were randomized in a double-blind, placebo-controlled, dose-ranging study conducted across 10 dermatology and plastic surgery centers in the United States (ATX-101-09-15). Subjects received one of two dosing regimens of ATX-101 (1 mg/cm2 or 2 mg/cm2) or placebo, administered monthly for up to 5 months into the submental area. Clinician assessments were performed at all treatment visits and 4 and 12 weeks after the last treatment visit (week 24 and week 32, respectively). Subject self-assessments and MRI assessments were performed at baseline, treatment visit 5 (week 16) and 12 weeks after the last treatment visit (week 32).
In this study, the 2 mg/cm2 proved to be the more efficacious dose and yielded a statistically significant reduction of unwanted submental fat compared to placebo as measured by physician assessment (p=0.001 and p=0.003, week 24 and week 32, respectively). Evidence of improvement was observed at 1 mg/cm2, indicating that a dose response exists between the two ATX-101 regimens. Physician assessment was performed using a validated, 5-point Clinician-Reported Submental Fat Rating Scale (CR-SMFRS). In addition, the 2 mg/cm2 dose group yielded a statistically significant reduction of submental fat as measured by subject assessment (p<0.05, week 16 and week 32). Subjects assessed submental fat using a 5-point Patient Reported Outcomes (PRO) tool, the Patient-Reported Submental Fat Rating Scale (PR-SMFRS).
“The results from this study are exciting and indicate the potential of ATX-101 as an effective and well-characterized treatment for the aesthetic reduction of small volumes of fat,” said Joel Schlessinger, MD, a board-certified dermatologist and cosmetic surgeon in private practice in Omaha, Nebraska and an investigator in this study. “There are currently no FDA-approved non-surgical treatment modalities for the reduction of fat under the chin. ATX-101 may represent a breakthrough for patients who are seeking a minimally-invasive treatment option for the reduction of unwanted localized submental fat.”